-
Motivation enhancement therapy with pregnant substance-abusing women: Does baseline motivation moderate efficacy?
Ondersma SJ, Winhusen TJ, Erickson SJ, Stine SM, Wang Y. Motivation enhancement therapy with pregnant substance-abusing women: Does baseline motivation moderate efficacy? Drug and Alcohol Dependence 2009;101(1-2):74-79.
-
The place of adoption in the NIDA Clinical Trials Network.
Jessup MA, Guydish JR, Manser ST, Tajima BM. The place of adoption in the NIDA Clinical Trials Network. Journal of Drug Issues 2008;38(4):1083-1104.
-
Extended vs. short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial.
Woody GE, Poole SA, Subramaniam GA, Dugosh KL, Bogenschutz MP, Abbott P, Patkar AA, Publicker M, McCain K, Sharpe Potter J, Formar RF, Vetter V, McNicholas L, Blaine J, Lynch KG, Fudala P. Extended vs. short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. JAMA 2008;300(17):2003-2011.
-
Research on the diffusion of evidence-based treatments within substance abuse treatment: A systematic review.
Garner BR. Research on the diffusion of evidence-based treatments within substance abuse treatment: A systematic review. Journal of Substance Abuse Treatment 2009;36(4):376-399.
-
Opioid treatment programs in the Clinical Trials Network: Representativeness and buprenorphine adoption.
Ducharme LJ, Roman PM. Opioid treatment programs in the Clinical Trials Network: Representativeness and buprenorphine adoption. Journal of Substance Abuse Treatment 2009;37(1):90-94.
-
Informal discussions in substance abuse treatment sessions.
Martino S, Ball SA, Nich C, Frankforter TL, Carroll KM. Informal discussions in substance abuse treatment sessions. Journal of Substance Abuse Treatment 2009;36(4):366-375. [doi: 10.1016/j.jsat.2008.08.003]
-
Quantifying data quality for clinical trials using electronic data capture.
Nahm ML, Pieper CF, Cunningham MM. Quantifying data quality for clinical trials using electronic data capture. PLoS ONE 2008;3(8):e3049.
-
Buprenorphine tapering schedule and illicit opioid use.
Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon JJ, Selzer JA, Boverman J, Bilangi R. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009;104(2):256-265 [doi: 10.1111/j.1360-0443.2008.02455.x]
-
Assessment and treatment of co-occurring eating disorders in publicly funded addiction treatment programs.
Gordon SM, Johnson JA, Greenfield SF, Cohen LR, Killeen T, Roman PM. Assessment and treatment of co-occurring eating disorders in publicly funded addiction treatment programs. Psychiatric Services 2008;59:1056-1059.
-
Serious adverse events in randomized psychosocial treatment studies: Safety or arbitrary edicts?
Petry NM, Roll JM, Rounsaville BJ, Ball SA, Stitzer ML, Peirce JM, Blaine J, Kirby KC, McCarty D, Carroll KM. Serious adverse events in randomized psychosocial treatment studies: Safety or arbitrary edicts? Journal of Consulting and Clinical Psychology 2008;76(6):1076-82.